OncoCyte Corporation (OCX): Price and Financial Metrics
OCX Price/Volume Stats
| Current price | $2.48 | 52-week high | $6.20 |
| Prev. close | $2.44 | 52-week low | $2.08 |
| Day low | $2.41 | Volume | 17,509 |
| Day high | $2.58 | Avg. volume | 47,490 |
| 50-day MA | $2.89 | Dividend yield | N/A |
| 200-day MA | $3.20 | Market Cap | 20.52M |
OCX Stock Price Chart Interactive Chart >
OncoCyte Corporation (OCX) Company Bio
OncoCyte Corporation focuses on developing diagnostic tests for the detection of breast, bladder, and lung cancers. The company was founded in 2009 and is based in Alameda, California.
Latest OCX News From Around the Web
Below are the latest news stories about ONCOCYTE CORP that investors may wish to consider to help them evaluate OCX as an investment opportunity.
Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays- Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte wi |
OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the HorizonStrategic Focus on Upcoming Product Launches Amidst Tightened Cash Burn Management |
Oncocyte Reports Third Quarter 2023 Financial Results-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial re |
Oncocyte to Announce Third Quarter 2023 Financial ResultsConference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ETIRVINE, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issu |
Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months EarlierOncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference. |
OCX Price Returns
| 1-mo | -16.78% |
| 3-mo | -20.77% |
| 6-mo | 8.77% |
| 1-year | -54.39% |
| 3-year | -97.52% |
| 5-year | -97.14% |
| YTD | -0.80% |
| 2023 | -61.05% |
| 2022 | -85.21% |
| 2021 | -9.21% |
| 2020 | 6.22% |
| 2019 | 63.04% |
Loading social stream, please wait...